Results 151 to 160 of about 14,491 (226)

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis. [PDF]

Qual Life Res
Huang Y, Chu Q, Wang J, Zhang L.
europepmc   +1 more source

Lung adenocarcinoma with <i>ALK</i> deletion of exons 6-20 with response to sequential ALK inhibitors: a case report. [PDF]

Transl Lung Cancer Res
Jinno K, Imabayashi T, Tanaka T, Yamamoto K, Tanaka S, Uda S, Yuba T, Takumi C.   +7 more
europepmc   +1 more source

Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study. [PDF]

ESMO Open
Sakaguchi H, Katayama R, Matsumoto M, Nishiyama A, Matsumoto K, Tajima A, Miyagi S, Toyama T, Mizuta H, Furugaki K, Yoshiura S, Takeuchi S.   +11 more
europepmc   +1 more source

Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors. [PDF]

Front Pharmacol
Gu J, Zhang J, Li S, Lin Z, Huang L, Zhou Y.   +5 more
europepmc   +1 more source

<i>In silico</i> repurposing of FDA-approved drugs against MEK1: structural and dynamic insights into lung cancer therapeutics. [PDF]

Front Pharmacol
Khan MS, Shamsi A, Zuberi A, Shahwan M.
europepmc   +1 more source

Alectinib Efficacy Post-Brigatinib Against Advanced <i>ALK</i>+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study). [PDF]

Lung Cancer (Auckl)
Descourt R, Guisier F, Pérol M, Cadranel J, Doubre H, Duruisseaux M, Culine S, Mennecier B, Bylicki O, Chouaid C, Greillier L.   +10 more
europepmc   +1 more source

Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report. [PDF]

Front Oncol
Lin M, Gao Y, Deng J.
europepmc   +1 more source

Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review. [PDF]

Cureus
Cheung BMF, El Helali A, Leung DKC.
europepmc   +1 more source

Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial. [PDF]

Nat Commun
Arrieta O, Lara-Mejía L, Rios-Garcia E, Caballé-Perez E, Cabrera-Miranda L, Ramos-Ramírez M, Dávila-Dupont D, Cardona AF, Cruz-Rico G, Remon J, Garcilazo-Reyes A, Rosell R.   +11 more
europepmc   +1 more source

Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors. [PDF]

Pharm Res
Takei Y, Kuroiwa H, Arai C, Doi Y, Semba K.   +4 more
europepmc   +1 more source